CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
University of Florida
Beijing Biotech
Sellas Life Sciences Group
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNC Lineberger Comprehensive Cancer Center
CellCentric Ltd.
BeOne Medicines
Kura Oncology, Inc.
Fred Hutchinson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Indapta Therapeutics, INC.
Thomas Jefferson University
M.D. Anderson Cancer Center
Takeda
Columbia University
Shenzhen TargetRx Co., Ltd.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bristol-Myers Squibb
Fate Therapeutics
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Molecular Templates, Inc.
Bellicum Pharmaceuticals
University of Michigan Rogel Cancer Center
Gamida Cell ltd
Novartis
Gamida Cell ltd
Chinese PLA General Hospital
Mirror Biologics, Inc.
Incyte Corporation
Chinese PLA General Hospital
Ciusss de L'Est de l'Île de Montréal
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Chinese PLA General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chinese PLA General Hospital
Gilead Sciences
Baylor College of Medicine
Keio University
Accenture
Duke University
M.D. Anderson Cancer Center